APOE and chronic kidney disease: As participants across all CKD stages studied (stage 0–3) were statistically comparable for AD risk factors, such as amyloid positivity, cognitive status, and APOE ε4 carrier status, differences observed in plasma biomarkers of AD and concomitant pathologies do not appear to be due to group differences in AD risk or pathology.